Phase 1 including first-in-human clinical trials to test biomarker-guided medicines or multi-modal treatment interventions for patients with rare or very rare cancers or cancer subtypes

What this call funds: research

Countries that may apply: European Union — any member state, Albania, Armenia, Bosnia & Herzegovina, Canada, Egypt, Faroe Islands, Georgia, Iceland, Israel, Japan, Kosovo, Moldova, Montenegro, New Zealand, North Macedonia, Norway, Serbia, South Korea, Switzerland, Tunisia, Türkiye, Ukraine, United Kingdom

Consortium: a consortium is required — You need at least 3 participants in total, including you, from 3 different countries

Who may apply: a commercial company may apply

Sector of the call: Health

Partners for this call

Partner search is available to registered users — sign up to see companies open to a consortium

How applications are chosen: competitive

· Does your organisation have a Gender Equality Plan?

· Does your work involve any of these?

· Are there any other ethics issues we should mention?

· Has your project changed substantially since the stage-1 proposal?

· Do you have a patent, an application or your own technology?

· How many people work with you today?

The funder sets no conditions after payment.